Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 222 results found since Jan 2013.

Incidental Uptake in a Subacute Stroke on 18F-Piflufolastat PSMA PET/CT
Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004798. Online ahead of print.ABSTRACTProstate-specific membrane antigen (PSMA) PET/CT has proven to be effective in the evaluation of prostate cancer and has become increasingly used clinically as multiple radiopharmaceuticals have become commercially available. With increasing use, incidental uptake from a variety of nononcologic processes will be encountered and considered interpretive pitfalls. We outline a case of a 71-year-old man who underwent imaging with PSMA PET/CT, which demonstrated uptake in the left parietal-temporal junction that was shown to be a subacut...
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Miles C Lewis Daniel J Wale Eric Liao Benjamin L Viglianti Source Type: research

Where You Live Can Shape How Alzheimer ’ s Affects You
The FDA in mid-July for the first time ever approved an Alzheimer’s drug, Leqembi. The annual price-tag will run patients $26,500. The same week, the Alzheimer’s Association for the first time ever released county-level data to identify which communities are most struggling with the disease. 6.7 million Americans live with Alzheimer’s disease and 134,000 of them will die because of it each year. We’ve known these aggregate numbers for a while now, but with new data and new drugs, healthcare specialists can now better target attention and resources. [time-brightcove not-tgx=”true”] ...
Source: TIME: Health - August 7, 2023 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news

Cheese consumption and multiple health outcomes: an umbrella review and updated meta-analysis of prospective studies
Adv Nutr. 2023 Jun 14:S2161-8313(23)01328-5. doi: 10.1016/j.advnut.2023.06.007. Online ahead of print.ABSTRACTThis umbrella review aims to provide a systematic and comprehensive overview of current evidence from prospective studies on the diverse health effects of cheese consumption. We searched PubMed, Embase, and Cochrane Library to identify meta-analyses/pooled analyses of prospective studies examining the associations between cheese consumption and major health outcomes from inception to August 31, 2022. We reanalyzed and updated previous meta-analyses and performed de novo meta-analyses with recently published prospec...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Mingjie Zhang Xiaocong Dong Zihui Huang Xue Li Yue Zhao Yingyao Wang Huilian Zhu Aiping Fang Edward L Giovannucci Source Type: research

Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer
Conclusions Cancer history is linked to increased risk of incident CVDs and adverse cardiac remodelling independent of shared vascular risk factors.
Source: Heart - June 14, 2023 Category: Cardiology Authors: Raisi-Estabragh, Z., Cooper, J., McCracken, C., Crosbie, E. J., Walter, F. M., Manisty, C. H., Robson, J., Mamas, M. A., Harvey, N. C., Neubauer, S., Petersen, S. E. Tags: Open access, Editor's choice, Press releases Cardiac risk factors and prevention Source Type: research

The Intersection of Prostate Cancer and Hypertension: a Call to Action
Opinion statementWith improvements in treatment and survival from prostate cancer, comorbid cardiac conditions will significantly impact overall morbidity and mortality from prostate cancer. Hypertension is a well-established cardiovascular risk factor that increases the risk of heart failure, myocardial infarction, and stroke. Therapies used in the treatment of prostate cancer, including GnRH agonists, GnRH antagonists, enzalutamide, abiraterone, and others, can directly or indirectly increase the risk of hypertension. In this paper, we review the evidence available on the incidence and mechanism of hypertension in prosta...
Source: Current Treatment Options in Oncology - May 16, 2023 Category: Cancer & Oncology Source Type: research

SNHG11 ：A New Budding Star in Tumors and Inflammatory Diseases
CONCLUSION: LncRNA SNHG11 can serve as an early diagnostic biomarker, therapeutic target, and prognostic indicator in various diseases, particularly tumors. SNHG11 plays a crucial role in the occurrence and development of tumors and inflammatory diseases through various mechanisms, which has significant implications for clinical diagnosis and treatment.PMID:37165588 | DOI:10.2174/1389557523666230509122402
Source: Mini Reviews in Medicinal Chemistry - May 11, 2023 Category: Chemistry Authors: Yinxin Wu Source Type: research

A man with left-sided weakness and numbness
Clinical introduction A 63-year-old right-handed man presented for evaluation of left leg stiffness and sensory change. He had a medical history of remote prostate cancer (status post resection in 2011). The patient reported that one week prior, he began noticing left leg stiffness and numbness, as well as left hand weakness and discoordination. He went to see his internist where he had a fall while the physician was testing his gait. He was sent to the emergency room (figure 1). He denied episodes of loss of consciousness, shaking, or headaches. He had no recent weight loss, night sweats, or previous falls. Question What ...
Source: Emergency Medicine Journal - April 21, 2023 Category: Emergency Medicine Authors: Gheihman, G., Paradis, X. G., ONeal, M. A. Tags: EMJ Image Challenge Source Type: research

Cancers, Vol. 15, Pages 2316: Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
K. Kelly Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, ...
Source: Cancers - April 15, 2023 Category: Cancer & Oncology Authors: James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly Tags: Review Source Type: research

Unknown Causes of Death in Cancer Patients
CONCLUSION: Of the patients, 7.4% died of unknown causes during follow-up and the proportion of death was higher with longer follow-up and among more indolent cancers. The attribution of high percentages of unknown COD to cancer or non-cancer causes could impact population-based cancer registry studies or clinical trial outcomes with respect to measures involving CSS and mortality.PMID:37038261 | DOI:10.1097/COC.0000000000001003
Source: Clinical Prostate Cancer - April 11, 2023 Category: Cancer & Oncology Authors: Siven Chinniah Mckenzee Chiam Kyle Mani Menglu Liang Daniel M Trifiletti Daniel E Spratt Vinayak K Prasad Ming Wang Leila T Tchelebi Nicholas G Zaorsky Source Type: research

Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study
CONCLUSIONS: GnRH antagonists may be associated with higher long-term, but not short-term, cardiovascular risks than agonists in Asian patients with PCa, particularly in those without known cardiovascular risk factors.PMID:37031076 | DOI:10.1016/j.clon.2023.03.014
Source: Clinical Prostate Cancer - April 8, 2023 Category: Cancer & Oncology Authors: J S K Chan Y H A Lee J M H Hui K Liu E C Dee K Ng P Tang G Tse C F Ng Source Type: research